About Us
History
Coronado is a biopharmaceutical company focused on novel immunotherapy biologic agents for autoimmune diseases and cancer. Coronado’s two principal pharmaceutical product candidates are initially targeted for clinical development for inflammatory bowel disease, multiple sclerosis and acute myeloid leukemia. The Company was incorporated in Delaware on June 28, 2006.
In January 2011, Coronado acquired the assets of Asphelia Pharmaceuticals, Inc. relating to CNDO-201, a novel immunotherapy being developed for the treatment of Crohn’s disease, ulcerative colitis and, multiple sclerosis and several other autoimmune disorders. These assets include exclusive rights to CNDO-201 in North America, South America and Japan under a sublicense agreement with OvaMed GmbH.
In November 2007, Coronado acquired from UCL Business PLC, an affiliate of University College London ("UCLB"), exclusive worldwide rights to develop and market CNDO-109, a compound that activates the natural killer ("NK") cells (known as Tumor Activated NK cells) of the host immune system to seek and destroy cancer cells, for the treatment of cancer. When activated, NK cells have the ability to differentiate between normal cells and cancer cells, and kill cancer cells by granzyme mediated lysis, a biochemical process whereby the NK cells directly kill cancer cells by destroying their cell structures. CNDO-109 has the potential to benefit patients with a wide variety of hematologic and solid cancers as data obtained from in vitro and in vivo preclinical studies of the product candidate conducted by UCL have demonstrated that CNDO-109 activated NK cells directly kill cells that cause hematologic malignancies including myeloid leukemia, multiple myeloma ("MM"), breast, prostate and ovarian cancers.
In January 2011, Coronado acquired the assets of Asphelia Pharmaceuticals, Inc. relating to CNDO-201, a novel immunotherapy being developed for the treatment of Crohn’s disease, ulcerative colitis and, multiple sclerosis and several other autoimmune disorders. These assets include exclusive rights to CNDO-201 in North America, South America and Japan under a sublicense agreement with OvaMed GmbH.
In November 2007, Coronado acquired from UCL Business PLC, an affiliate of University College London ("UCLB"), exclusive worldwide rights to develop and market CNDO-109, a compound that activates the natural killer ("NK") cells (known as Tumor Activated NK cells) of the host immune system to seek and destroy cancer cells, for the treatment of cancer. When activated, NK cells have the ability to differentiate between normal cells and cancer cells, and kill cancer cells by granzyme mediated lysis, a biochemical process whereby the NK cells directly kill cancer cells by destroying their cell structures. CNDO-109 has the potential to benefit patients with a wide variety of hematologic and solid cancers as data obtained from in vitro and in vivo preclinical studies of the product candidate conducted by UCL have demonstrated that CNDO-109 activated NK cells directly kill cells that cause hematologic malignancies including myeloid leukemia, multiple myeloma ("MM"), breast, prostate and ovarian cancers.